• Who we are
  • Key topics
  • Publications
  • Newsroom
  • JOB OPPORTUNITIES
  • Contact us
Login Login
Medicines for Europe
  • Generic medicines
    • Home
    • Medicines for Europe
      • Generic medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Definition
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Biosimilar medicines
    • Home
    • Medicines for Europe
      • Biosimilar medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • DEFINITION
      • THERAPEUTIC AREAS
      • GLOSSARY
      • Q&A
    • What’s new
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
      • External resources
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Related links
      • Contact us
    • Twitter
  • Value added medicines
    • Home
    • Who we are
      • Value added medicines Group
      • MISSION AND VISION
      • STRUCTURE
      • MEMBERS
      • BECOME A MEMBER
    • Did you know?
      • Environment of value added medicines in Europe
      • Definition
      • THERAPEUTIC AREAS
      • Q&A
    • What’s new
      • Environment of value added medicines in Europe
      • FACTSHEETS
      • POLICY
      • REPORTS
      • VIDEOS
      • INFOGRAPHICS
      • Value Added Medicines award 2019
      • QUOTES
    • Our 5 pillars
      • Patients
      • QUALITY
      • VALUE
      • SUSTAINABILITY
      • PARTNERSHIP
    • Find out more
      • Contact us
  • Events

IGBA Calls on all Stakeholders to Join the Biosimilars Movement on Advancing Access

1 November 2021

Read more

Related Posts

  • Advancing Medicines repurposing in the EU 14 March 2022 Repurposing has emerged as an important strategy to address unmet…
  • Interview: Medicines for Europe Reports on EU Biosimilar… 27 July 2020 The Center for Biosimilars® (CfB) spoke with Adrian van den Hoven,…
  • IGBA Launches First Global Biosimilars Week 16 November 2020
  • Opinion piece by Christoph Stoller for Friends of Europe 3 June 2021 "Too much at stake in the EU pharma strategy to…
Medicines for Europe
MEMBER OF
IGBA EMVO
  • Contact us
  • Privacy Policy
Medicines for Europe AISBL
Rue d’Arlon 50
1000 Brussels Belgium
T : +32 (0)2 736 84 11
Powered by Big Smile Agency
Medicines For Europe
  • Who we are
  • Key topics
  • Publications
  • Newsroom
  • Contact us
  • SECTOR GROUPS
    • Generic medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Biosimilar medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
      • FIND OUT MORE
    • Value added medicines
      • WHO WE ARE
      • DID YOU KNOW?
      • WHAT’S NEW
      • OUR 5 PILLARS
  • Events
  • JOB OPPORTUNITIES
 Tweet
 Tweet
 Tweet
 LinkedIn